Prestige Consumer Healthcare (NYSE:PBH) Releases Earnings Results, Beats Expectations By $0.04 EPS

Prestige Consumer Healthcare (NYSE:PBH) announced its earnings results on Thursday. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.18 by $0.04, Zacks reports. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. Prestige Consumer Healthcare updated its FY 2025 guidance to 4.500-4.500 EPS.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH traded up $0.44 during trading on Friday, reaching $87.79. 37,090 shares of the company traded hands, compared to its average volume of 295,244. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare has a 52 week low of $60.00 and a 52 week high of $87.61. The firm has a market capitalization of $4.34 billion, a PE ratio of 21.39, a PEG ratio of 2.15 and a beta of 0.50. The company’s 50 day moving average is $79.19 and its two-hundred day moving average is $75.34.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PBH. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. DA Davidson reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a report on Monday, December 9th. Finally, StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $85.25.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now owns 18,365 shares of the company’s stock, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock valued at $3,187,300 over the last quarter. 1.60% of the stock is owned by corporate insiders.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.